Results from a new study suggest that the presence of circulating tumor DNA (ctDNA) in blood samples can predict which patients with colorectal cancer should and shouldn’t get chemotherapy after surgery to remove their tumors.
Using two different techniques, researchers showed they could temporarily boost ctDNA levels in the blood of mice with tumors. With more ctDNA in collected blood draws, a liquid biopsy could better detect cancer, the research team found.
The results of the clinical trial that led to FDA’s 2023 approval of repotrectinib (Augtyro) for lung cancers with ROS1 fusions have been published. The drug shrank tumors in 80% of people receiving the drug as an initial treatment.
In a new study in mice, researchers showed they could enhance radiation therapy by boosting levels of the BAMBI protein in MDSC immune cells in the tumor microenvironment. After radiation, T cells flooded into the tumor and killed tumors elsewhere in the body.
Training provided by NCI scientists helped researchers in India design an effective CAR-T cell therapy, NexCAR19, that can be manufactured in India, made available at a reasonable cost, and meet the needs of patients in India’s health care system.